INCB018424, a Selective Inhibitor of JAK1 and JAK2, Downregulates the Expression of Leukocyte Alkaline Phosphatase (LAP) On Circulating Granulocytes in Patients with Polycythemia Vera and Essential Thrombocythemia

被引：0
|
作者：
Passamonti, Francesco [1 ]
Rumi, Elisa [1 ]
Della Porta, Matteo G. [1 ]
Portolan, Monica [1 ]
Elena, Chiara [1 ]
Arcaini, Luca [1 ]
Pascutto, Cristiana [1 ]
Vanelli, Laura [1 ]
Vaddi, Kris [2 ]
Lazzarino, Mario [1 ]
Cazzola, Mario [1 ]
机构：
[1] Univ Pavia, Dept Hematol Oncol, Fdn IRCCS Policlin San Matteo, I-27100 Pavia, Italy
[2] Incyte Corp, Wilmington, DE USA
来源：
BLOOD | 2009年 / 114卷 / 22期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1135 / 1135
页数：1
相关论文
共 50 条
  • [41] A higher JAK2 V617F-mutated clone is observed in platelets than in granulocytes from essential thrombocythemia patients, but not in patients with polycythemia vera and primary myelofibrosis
    B Bellosillo
    L Martínez-Avilés
    E Gimeno
    L Florensa
    R Longarón
    G Navarro
    A Salar
    B Espinet
    F Solé
    S Serrano
    C Besses
    Leukemia, 2007, 21 : 1331 - 1332
  • [42] A higher JAK2 V617F-mutated clone is observed in platelets than in granulocytes from essential thrombocythemia patients, but not in patients with polycythemia vera and primary myelofibrosis
    Bellosillo, B.
    Martinez-Aviles, L.
    Gimeno, E.
    Florensa, L.
    Longaron, R.
    Navarro, G.
    Salar, A.
    Espinet, B.
    Sole, F.
    Serrano, S.
    Besses, C.
    LEUKEMIA, 2007, 21 (06) : 1331 - 1332
  • [43] MicroRNA Expression and JAK2 Allele Burden in Bone Marrow Trephine Biopsies of Polycythemia Vera, Essential Thrombocythemia and Early Primary Myelofibrosis
    Gebauer, Niklas
    Bernard, Veronica
    Gebauer, Wolfgang
    Feller, Alfred C.
    Merz, Hartmut
    ACTA HAEMATOLOGICA, 2013, 129 (04) : 251 - 256
  • [44] Phase II Study of the JAK2 Inhibitor, INCB018424, In Patients with Refractory Leukemias Including Post-Myeloproliferative Disorder (MPD) Acute Myeloid Leukemia (sAML)
    Eghtedar, Alireza
    Verstovsek, Srdan
    Cortes, Jorge E.
    Estrov, Zeev
    Burger, Jan A.
    Bivins, Carol
    Faderl, Stefan
    Ferrajoli, Alessandra
    Borthakur, Gautam
    George, Solly
    Newton, Robert
    Kantarjian, Hagop
    Ravandi, Farhad
    BLOOD, 2010, 116 (21) : 225 - 225
  • [45] PHASE II STUDY OF CEP-701, AN ORALLY AVAILABLE JAK2 INHIBITOR, IN PATIENTS WITH PRIMARY MYELOFIBROSIS AND POST POLYCYTHEMIA VERA/ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS
    Santos, F. P. S.
    Kantarjian, H.
    Jain, N.
    Thomas, D.
    Garcia-Manero, G.
    Cortes, J.
    Verstovsek, S.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 439 - 439
  • [46] Hydroxyurea does not appreciably reduce JAK2 V617F allele burden in patients with polycythemia vera or essential thrombocythemia
    Antonioli, Elisabetta
    Carobbio, Alessandra
    Pieri, Lisa
    Pancrazzi, Alessandro
    Guglielmelli, Paola
    Delaini, Federica
    Ponziani, Vanessa
    Bartalucci, Niccolo
    Tozzi, Lorenzo
    Bosi, Alberto
    Rambaldi, Alessandro
    Barbui, Tiziano
    Vannucchi, Alessandro M.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 (08): : 1435 - 1438
  • [47] JAK2 V617F allele burden and hemostatic profile of essential thrombocythemia (ET) and polycythemia vera (PV) patients
    Marchetti, M.
    Castoldi, E.
    Russo, L.
    Vignoli, A.
    Rosing, J.
    ten Cate, H.
    Falanga, A.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2009, 7 : 795 - 796
  • [48] Phase II study of CEP701, an orally available JAK2 inhibitor, in patients with primary myelofibrosis and post polycythemia vera/essential thrombocythemia myelofibrosis
    Verstovsek, Srdan
    Tefferi, Ayalew
    Korriblau, Steven
    Thomas, Deborah
    Cortes, Jorge
    Ravandi-Kashani, Farhad
    Garcia-Manero, Guillermo
    Kantarjian, Hagop
    BLOOD, 2007, 110 (11) : 1037A - 1037A
  • [49] Characterization of JAK2 V617F Allele Burden in Advanced Myelofibrosis (MF) Patients: No Change in V617F:WT JAK2 Ratio in Patients with High Allele Burdens despite Profound Clinical Improvement Following Treatment with the JAK Inhibitor, INCB018424
    Verstovsek, Srdan
    Kantarjian, Hagop M.
    Pardanani, Animesh D.
    Burn, Timothy
    Vaddi, Kris
    Redman, John
    Bradley, Edward C.
    Levy, Richard
    Friedman, Steven
    Hollis, Gregory
    Tefferi, Ayalew
    BLOOD, 2008, 112 (11) : 968 - 968
  • [50] GENE EXPRESSION PROFILE IN JAK2 V617F POSITIVE POLYCYTHEMIA VERA AND ESSENTIAL THROMBOCYTHEMIA RELATED TO RESPONSE TO HYDROXYUREA TREATMENT
    Miguel, G.
    Santiago, S.
    Enriqueta, A.
    Inmaculada, I.
    Rosa, R.
    Jimenez, A.
    Daniel, D.
    Eulalia, E.
    Blanca, B.
    Lourdes, L.
    Carles, C.
    Joaquin, J.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 400 - 401
12345